'Clinically Meaningful' Improvement in SCLC Patients With Pembrolizumab/Chemo Combo

(MedPage Today) -- VIENNA -- Long-term results from the phase III KEYNOTE-604 trial appeared to strengthen the case of pembrolizumab (Keytruda) combined with platinum etoposide as a first-line treatment for patients with extensive-stage small cell...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news